Osborne Clarke has advised B2B food start-up Nosh.bio GmbH on its recent EUR 3.2 million seed funding round.
Animal-free nutrition that is healthier, tastier, less processed and more affordable than products with animal protein: That is the goal of Nosh.bio. Founded in February 2022 by reBuy founder Tim Fronzek and Felipe Lino, the Berlin-based start-up wants to transform the food industry so that it is no longer harmful to the environment, animals or humans. To achieve this, animal-free proteins are to become the main source of protein in the human diet.
Nosh.bio uses fermented mycoprotein to produce a plant-based protein alternative for further use in various foods. As a business partner for manufacturers of animal-free products, the start-up ensures highly functional, healthy and clean-label ingredients at the same price as animal products.
To drive the commercialisation of its first product, the development of R&D processes and the expansion of production capacity, Nosh.bio has now secured EUR 3.2 million. The seed funding round was led by Earlybird Venture Capital; Clear Current Capital, Grey Silo Ventures and Good Seed Ventures co-invested.
The team advising Nosh.bio, led by Till-Manuel Saur, consisted of Giovanni Alexandrov, Philipp Niedermeyer (all Corporate/VC), Dr Andrea Schmoll, Lotte Mues and Dr Jonas Völkel (all IP).